Key Points
- CEO Yujiro Hata sold 26,338 IDEAYA Biosciences shares at an average price of $37.41, generating approximately $985,305; his remaining direct ownership fell 3.67% to 690,695 shares.
- IDEAYA shares opened at $36.06, with a market capitalization of about $3.17 billion. The company’s latest quarter missed EPS expectations, reporting a loss of $1.22 per share despite revenue of $8.86 million.
- Analysts maintain a “Moderate Buy” consensus, with 13 Buy, one Hold and one Sell rating and an average price target of $52.69; institutional investors own 98.29% of the stock.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) CEO Yujiro Hata sold 26,338 shares of the company's stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total transaction of $985,304.58. Following the sale, the chief executive officer directly owned 690,695 shares of the company's stock, valued at approximately $25,838,899.95. This represents a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
IDEAYA Biosciences Trading Down 0.6%
NASDAQ:IDYA opened at $36.06 on Friday. IDEAYA Biosciences, Inc. has a 1 year low of $26.05 and a 1 year high of $42.68. The firm's fifty day simple moving average is $38.13 and its 200 day simple moving average is $34.29. The firm has a market capitalization of $3.17 billion, a PE ratio of -18.59 and a beta of -0.04.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.06) by ($0.16). The firm had revenue of $8.86 million for the quarter, compared to analyst estimates of $8.02 million. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%.The firm's revenue was up 8800.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.88) EPS. As a group, analysts anticipate that IDEAYA Biosciences, Inc. will post -4.38 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research firms have recently commented on IDYA. Guggenheim lifted their price objective on IDEAYA Biosciences from $54.00 to $57.00 and gave the stock a "buy" rating in a research note on Wednesday, September 9th. Weiss Ratings restated a "sell (d-)" rating on shares of IDEAYA Biosciences in a research note on Friday, July 17th. Citigroup reaffirmed a "market outperform" rating on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Citizens Jmp reiterated a "market outperform" rating and set a $42.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Finally, Truist Financial reduced their price objective on IDEAYA Biosciences from $63.00 to $59.00 and set a "buy" rating for the company in a research report on Wednesday, August 5th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, IDEAYA Biosciences has a consensus rating of "Moderate Buy" and a consensus target price of $52.69.
Get Our Latest Report on IDYA
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Quantbot Technologies LP acquired a new stake in IDEAYA Biosciences during the second quarter worth about $43,000. Nykredit A S bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $76,000. Fifth Third Bancorp bought a new stake in shares of IDEAYA Biosciences in the 1st quarter worth approximately $84,000. GAMMA Investing LLC grew its holdings in shares of IDEAYA Biosciences by 79.0% during the 3rd quarter. GAMMA Investing LLC now owns 2,315 shares of the company's stock worth $89,000 after purchasing an additional 1,022 shares in the last quarter. Finally, Versant Capital Management Inc grew its holdings in shares of IDEAYA Biosciences by 26.7% during the 2nd quarter. Versant Capital Management Inc now owns 2,825 shares of the company's stock worth $105,000 after purchasing an additional 596 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.
About IDEAYA Biosciences
(
Get Free Report)
IDEAYA Biosciences, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights from tumor biology, cancer genetics and synthetic lethality to identify treatments designed to target specific molecular alterations in tumors.
Its development pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily in genetically defined cancers, including GNAQ- or GNA11-mutated uveal melanoma.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
